CLLS Company Profile and Key Details

Q: Who are the executives of CLLS?

Ms. Kyung Nam-WortmanExecutive Vice President & Chief HR OfficerMs. Marie-Bleuenn TerrierGen. Counsel & Sec. of the Board of DirectorsDr. Andre Choulika Ph.D.Co-Founder, Chief Executive Officer & DirectorDr. David J. D. Sourdive Ph.D.Deputy Chief Executive Officer, Executive Vice President of CMC & Manufacturing and DirectorrDr. Bing C. Wang M.B.A., Ph.D.Chief Financial OfficerValerie CrosPrincipal Financial Officer & Principal Accounting OfficerMr. Jean Charles EpinatChief Technological OfficerDr. Philippe Duchateau Ph.D.Chief Scientific OfficerMr. Stephan Reynier M.Sc., MScChief Regulatory & Pharmaceutical Compliance OfficerPascalyne WilsonDirector of Communications

NASDAQ : CLLS

Cellectis SA

$3.99

-0.07-1.72%

At Close 4:00 PM

52.55

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Cellectis S.A. (CLLS) stock declined over -1.72%, trading at $3.99 on NASDAQ, down from the previous close of $4.06. The stock opened at $4.02, fluctuating between $3.90 and $4.02 in the recent session.

Stock Snapshot

4.06

Prev. Close

400.22M

Market Cap

3.9

Day Low

-12.09

P/E Ratio

-0.33

EPS (TTM)

-1.14

Cash Flow per Share

4.02

Open

100.3M

Number of Shares

4.0239

Day High

85.72%

Free Float in %

1.37

Book Value

3.67K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 19, 2026	4.02	4.02	3.90	3.99	6.14K
Feb 18, 2026	3.88	4.06	3.88	4.06	12.57K
Feb 17, 2026	3.73	3.93	3.73	3.88	20.5K
Feb 13, 2026	3.71	3.90	3.69	3.73	36.18K
Feb 12, 2026	3.70	3.71	3.44	3.49	44.12K
Feb 11, 2026	3.78	3.80	3.61	3.65	15.24K
Feb 10, 2026	3.84	3.98	3.71	3.89	50.78K
Feb 09, 2026	3.78	3.81	3.69	3.72	34.6K
Feb 06, 2026	3.66	3.66	3.49	3.57	18.8K
Feb 05, 2026	3.68	3.69	3.44	3.50	86.4K
Feb 04, 2026	3.64	3.76	3.49	3.54	78.96K
Feb 03, 2026	3.82	3.83	3.53	3.53	75.12K
Feb 02, 2026	3.76	3.95	3.76	3.82	12.76K
Jan 30, 2026	3.90	3.91	3.78	3.79	26.47K
Jan 29, 2026	3.99	4.01	3.81	3.99	35.32K
Jan 28, 2026	4.17	4.17	4.00	4.06	32.85K
Jan 27, 2026	4.12	4.28	4.12	4.23	21.56K
Jan 26, 2026	4.33	4.33	4.04	4.08	65.94K
Jan 23, 2026	4.29	4.50	4.29	4.42	11.95K
Jan 22, 2026	4.13	4.39	4.13	4.37	44.12K

Contact Details

Paris, 75013

France

https://www.cellectis.com 331 816 91600

About Company

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Stock Peers

ARGX

1.91+0.23%

argenx SE$847.26 REGN

-9.78-1.23%

Regeneron Pharmaceuticals, Inc.$782.38 UTHR

4.47+0.94%

United Therapeutics Corporation$480.52 VRTX

-1.04-0.22%

Vertex Pharmaceuticals Incorporated$469.27 MDGL

-54.62-11.11%

Madrigal Pharmaceuticals, Inc.$436.87 ALNY

6.69+2.01%

Alnylam Pharmaceuticals, Inc.$339.37 PRAX

2.68+0.81%

Praxis Precision Medicines, Inc.$331.61 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

-20.62-7.28%

Krystal Biotech, Inc.$262.67 ASND

3.38+1.49%

Ascendis Pharma A/S$230.21

Frequently Asked Questions

What is the current Cellectis S.A. (CLLS) stock price?

Cellectis S.A. (NASDAQ: CLLS) stock price is $3.99 in the last trading session. During the trading session, CLLS stock reached the peak price of $4.02 while $3.90 was the lowest point it dropped to. The percentage change in CLLS stock occurred in the recent session was -1.72% while the dollar amount for the price change in CLLS stock was - $0.07.

CLLS's industry and sector of operation?

The NASDAQ listed CLLS is part of Biotechnology industry that operates in the broader Healthcare sector. Cellectis S.A. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CLLS?

Ms. Kyung Nam-Wortman
Executive Vice President & Chief HR Officer
Ms. Marie-Bleuenn Terrier
Gen. Counsel & Sec. of the Board of Directors
Dr. Andre Choulika Ph.D.
Co-Founder, Chief Executive Officer & Director
Dr. David J. D. Sourdive Ph.D.
Deputy Chief Executive Officer, Executive Vice President of CMC & Manufacturing and Directorr
Dr. Bing C. Wang M.B.A., Ph.D.
Chief Financial Officer
Valerie Cros
Principal Financial Officer & Principal Accounting Officer
Mr. Jean Charles Epinat
Chief Technological Officer
Dr. Philippe Duchateau Ph.D.
Chief Scientific Officer
Mr. Stephan Reynier M.Sc., MSc
Chief Regulatory & Pharmaceutical Compliance Officer
Pascalyne Wilson
Director of Communications

How CLLS did perform over past 52-week?

CLLS's closing price is 262.73% higher than its 52-week low of $1.10 where as its distance from 52-week high of $5.48 is -27.19%.

How many employees does CLLS have?

Number of CLLS employees currently stands at 216.

Link for CLLS official website?

Official Website of CLLS is: https://www.cellectis.com

How do I contact CLLS?

CLLS could be contacted at phone 331 816 91600 and can also be accessed through its website. CLLS operates from 8, rue de la Croix Jarry, Paris, 75013, France.

How many shares of CLLS are traded daily?

CLLS stock volume for the day was 3.67K shares. The average number of CLLS shares traded daily for last 3 months was 86.74K.

What is the market cap of CLLS currently?

The market value of CLLS currently stands at $400.22M with its latest stock price at $3.99 and 100.3M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	216
Beta	2.85
Sales or Revenue	$19.17M
5Y Sales Change%	-0.954%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	216
Beta	2.85
Sales or Revenue	$19.17M
5Y Sales Change%	-0.954%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CLLS Company Profile and Key Details

Cellectis SA

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Price Forecast & Outlook

Key Takeaways

Valuation Metrics